Beximco Pharmaceuticals Ltd AGM Change and Dividend Update (4112X)
May 06 2016 - 2:01AM
UK Regulatory
TIDMBXP
RNS Number : 4112X
Beximco Pharmaceuticals Ltd
06 May 2016
BEXIMCO PHARMACEUTICALS LTD.
6 May 2016
Postponement of Annual General Meeting and Dividend update
("Beximco Pharma", "BPL" or "the Company")
Beximco Pharmaceuticals Ltd. (AIM Symbol: BXP), the fast-growing
manufacturer of generic pharmaceutical products and active
pharmaceutical ingredients, announces that, as a consequence of its
change of accounting reference date to 30 June announced today, the
40(th) Annual General Meeting of the Company ("AGM"), declared for
4 June 2016 is hereby postponed. The AGM will now be held before
the end of this calendar year and will consider, inter alia, the
adoption of the Company's audited report and accounts for the 18
month period ending on 30 June 2016, which is the new financial
year end of the Company.
In addition, in the preliminary results announcement dated 21
April 2016, the Company made certain announcements in relation to
dividends relating to the 12 month period ended 31 December
2015.
As a result of the change of the accounting reference date and
the postponement of the AGM, the Company now wishes to clarify the
following:
-- That the record date for entitlement of 10% cash and 5% stock
dividend, which was declared to be 12 May 2016, shall remain
unchanged; and
-- That the 10% cash dividend declared by the Company, will be
paid on or before 4 July, 2016. The 5% Stock dividend will be
issued subject to the approval of the shareholders at the
forthcoming AGM.
Ends
For further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company
Secretary
Tel: +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Sean Wyndham-Quin
Tel: +44 (0)20 3368 3551 / 3555
Daniel Stewart & Company plc (Broker)
Martin Lampshire
Tel: +44 (0)20 7776 6550
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors:
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma
manufactures and sells generic pharmaceutical formulation products
and active pharmaceutical ingredients. The Company also undertakes
contract manufacturing for multinational and leading global generic
pharmaceutical companies. The Company operates from a 23 acre site
in Dhaka and has manufacturing facilities for producing various
drugs in different delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, prefilled syringes,
injectables, nebulizer solutions, oral soluble films etc. Ensuring
access to quality medicines is the powerful aspiration that
motivates 3,000 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of Australia, Europe,
Latin America, Canada and the US, among others. The Company's
products are sold to retail outlets, medical institutions and other
pharmaceutical manufacturers in Bangladesh, in regional markets
such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and
in other markets overseas, principally in Africa, including South
Africa, Mauritius, Kenya, Ghana, Ethiopia and Nigeria; Pacific
Island; Latin and Central American countries; Middle East; Central
Asia; South East Asia, including Singapore, Malaysia, Indonesia,
Philippines and Hong Kong; Europe, including Austria, Germany and
Romania and Australia.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGUAGAUPQGCA
(END) Dow Jones Newswires
May 06, 2016 02:01 ET (06:01 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2023 to Apr 2024